Chronic Pain Market Summary

• According to DelveInsight’s analysis, the Chronic Pain Therapeutics Market Size was ~USD 15 billion in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• The Chronic Pain Companies include AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.

Chronic Pain Market & Epidemiology Insight

• In 2025, the total number of diagnosed prevalent cases of Chronic Pain in the 7MM was ~115 million. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases ~45 million.
• The Chronic Pain analysis included six key underlying pain conditions: Chronic Back Pain, Osteoarthritis, Rheumatoid Arthritis, Migraine, Fibromyalgia, and Neuropathic Pain, representing the indications considered within the scope of the analysis across the 7MM.
• The Chronic Pain Marketed Landscape remains highly fragmented, reflecting the heterogeneity of chronic pain itself. Migraine has developed into the most targeted segment, with CGRP therapies such as EMGALITY, VYEPTI, AIMOVIG, and AJOVY, alongside BOTOX, establishing specialized preventive treatment pathways. In contrast, osteoarthritis and neuropathic pain continue to rely on a combination of localized therapies, anticonvulsants, and analgesics, highlighting significant differences in therapeutic innovation and market maturity across pain conditions.
• The Chronic Pain Therapeutics Market landscape is increasingly differentiated by pain etiology, with CGRP-targeted therapies dominating migraine prevention, intra-articular therapies addressing osteoarthritis pain, a2d-ligands and topical agents targeting neuropathic pain, and non-opioid approaches emerging for chronic lower back pain (CLBP). At the same time, opioids remain an important treatment option for selected patients with severe chronic pain despite increasing emphasis on risk-benefit assessment and opioid-sparing strategies.
• An aging population of older adults, especially those 65 and over, contributes to a growing chronic pain patient pool because of the growing burden of musculoskeletal and neuropathic conditions, including osteoarthritis, chronic back pain, and migraine. The patient pool is likely to favor treatments that can provide durable control while remaining suitable for long-term management.
• The ongoing research in chronic pain aims to address the limitations of currently available therapies through the development of novel and targeted approaches, with emerging assets including SL1002 by Saol Therapeutics, Zenagamtide by Novo Nordisk, incobotulinumtoxinA (XEOMIN) by Merz Therapeutics, among others, reflecting a diverse and evolving pipeline.

Chronic Pain Market Size and Forecast in the 7MM

Key Factors Driving the Growth of the Chronic Pain Market

• Rising Prevalence of Chronic Pain Conditions

The increasing prevalence of chronic pain associated with conditions such as osteoarthritis, neuropathic pain, low back pain, fibromyalgia, and cancer is expanding the patient population requiring long-term pain management. Aging populations and the growing burden of chronic diseases are further contributing to market demand.

• Growing Adoption of Novel Pain Management Therapies

Advances in pharmacological treatments, including non-opioid analgesics, targeted therapies, neuromodulators, and long-acting formulations, are broadening treatment options for patients with chronic pain. The development of therapies with improved efficacy and more targeted mechanisms is supporting market expansion.

• Increasing Focus on Non-Opioid and Multimodal Pain Management

Concerns surrounding opioid dependence, misuse, and adverse effects have encouraged healthcare providers and pharmaceutical companies to explore non-opioid alternatives and multimodal treatment approaches. This shift is creating opportunities for innovative pharmacological and non-pharmacological pain management solutions.

• Technological Advancements in Pain Management

Technological innovations such as neuromodulation devices, spinal cord stimulation, digital therapeutics, wearable technologies, and remote patient monitoring are transforming chronic pain management. These technologies can enable more personalized treatment approaches and improve ongoing disease monitoring.

• Increasing Investment in R&D and Emerging Therapies

Growing pharmaceutical and biotechnology investment in novel mechanisms of action, precision pain medicine, regenerative approaches, and targeted therapies is strengthening the chronic pain development pipeline. Increasing clinical research activity is expected to introduce new treatment options and address significant unmet needs in chronic pain management.

DelveInsight’s “Chronic Pain Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of chronic pain, historical and forecasted epidemiology, as well as the chronic pain market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The Chronic Pain Treatment Market Report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, chronic pain patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022–2036) across the 7MM regions. The report highlights key unmet medical needs in chronic pain and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Chronic Pain Understanding

Chronic Pain Overview

Chronic pain is a complex and persistent condition defined as pain lasting beyond the normal healing period, typically for more than 3–6 months. It affects a substantial proportion of the adult population and is associated with significant physical, psychological, and socioeconomic burden. Chronic pain may arise from tissue injury, disease, nerve damage, or altered pain processing, and is frequently accompanied by comorbid conditions such as depression and anxiety, which further impair quality of life and functional capacity. The condition is also associated with increased healthcare utilization, reduced productivity, opioid misuse, and elevated mortality risk.

Chronic Pain Diagnosis

The diagnosis of chronic pain requires a comprehensive and multidisciplinary evaluation aimed at identifying the underlying cause, determining the predominant pain mechanism, and assessing the impact of pain on physical, psychological, and social functioning. Because chronic pain may arise from musculoskeletal, neuropathic, inflammatory, visceral, or nociplastic mechanisms, diagnosis is based on a combination of clinical assessment and targeted diagnostic investigations.

A thorough physical examination helps identify structural, neurological, or inflammatory abnormalities that may contribute to chronic pain. Examination typically includes assessment of posture, gait, joint range of motion, muscle strength, tenderness, swelling, sensory changes, reflexes, and signs of nerve compression or musculoskeletal dysfunction.

Further details related to country-based variations are provided in the report…

Current Chronic Pain Treatment Landscape

The management of chronic pain requires a multimodal and individualized approach that addresses pain intensity, functional impairment, psychological comorbidities, and the underlying pain mechanism. Because chronic pain may be nociceptive, neuropathic, inflammatory, visceral, or nociplastic in origin, treatment is typically tailored to the predominant mechanism and the patient’s clinical profile. Current management combines pharmacological therapies, non-pharmacological interventions, interventional procedures, and multidisciplinary rehabilitation, with the goal of improving function and quality of life rather than eliminating pain completely.

Non-opioid analgesics such as acetaminophen and NSAIDs are considered first-line therapies for many chronic musculoskeletal conditions, while opioids are generally reserved for severe, persistent, or refractory pain when non-opioid therapies have failed or are contraindicated. Other commonly used pharmacological treatments include anticonvulsants and antidepressants, particularly for neuropathic, nociplastic, fibromyalgia, and chronic musculoskeletal pain.

Topical therapies such as lidocaine, capsaicin, and topical NSAIDs may be used for localized neuropathic or musculoskeletal pain. Treatment is generally individualized and requires ongoing reassessment of pain relief, physical function, mental health, medication-related harms, and patient-centered goals.

Further details related to country-based variations are provided in the report…

Chronic Pain Unmet Needs

The section “unmet needs of chronic pain” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

• Heterogeneous disease biology and absence of predictive biomarkers limit precision treatment 
• Persistent reliance on symptomatic analgesia limits long-term disease management
• High unmet need for durable, long-acting therapies continues to drive repeat treatment burden
• Heterogeneous epidemiological evidence limits accurate market sizing across chronic pain indications, and others…

Note: Comprehensive unmet needs insights in chronic pain and their strategic implications are provided in the full report…

Chronic Pain Epidemiology Insights in the 7MM

Key Findings from Chronic Pain Epidemiological Analysis and Forecast

• In 2025, the total number of diagnosed prevalent cases of chronic pain in the 7MM was around 115 million. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases, contributing approximately 45 million cases.
• According to DelveInsight’s analysis, more than 20 million males and 20 million females were affected by chronic pain in the US in 2025, depicting a clear gender disparity due to hormonal factors.
• Across EU4 and the UK, approximately 50 million diagnosed prevalent cases of chronic pain were reported in 2025. Germany accounted for the largest share, contributing around 15 million diagnosed prevalent cases, followed by France.
• According to DelveInsight’s estimates, moderate chronic pain accounted for the highest number of diagnosed prevalent cases across EU4 and the UK in 2025, with approximately 25 million cases, followed by mild (10 million cases) and severe (15 million cases).
• Japan accounted for nearly 20 million diagnosed prevalent cases of chronic pain in 2025.
• The chronic pain landscape is characterized by a persistent gap between total prevalent and diagnosed cases, particularly in the US, where the diagnosed population remains substantially below the overall prevalent population. This pattern indicates that the chronic pain burden extends beyond the currently recognized treatment population, leaving room for further patient identification through improved diagnosis and healthcare engagement. As diagnosis expands, the resulting increase in treatment-eligible patients could complement the underlying epidemiological growth and broaden the market for chronic pain therapies.

Chronic Pain Epidemiology Segmentation in the 7MM

• Total Chronic Pain Prevalent Cases
• Total Chronic Pain Diagnosed Prevalent Cases
• Chronic Pain Severity -specific Diagnosed Prevalent Cases
• Chronic Pain Gender-specific Diagnosed Prevalent Cases
• Chronic Pain Age-specific Diagnosed Prevalent Cases
• Chronic Pain Cause-specific Diagnosed Prevalent Cases
• Total Chronic Pain Treated Cases

Chronic Pain Market Recent Breakthroughs and Developments

• In July 2026, Ipsen reported positive topline results from the Phase III BEOND migraine program evaluating abobotulinumtoxinA (DYSPORT) for the prevention of episodic and chronic migraine in adults.
• In July 2026, Mesoblast announced that it had achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase III randomized controlled trial of rexlemestrocel-L for CLBP.
• In July 2026, Paradigm Biopharmaceuticals completed enrolment in its global Phase III trial of injectable pentosan polysulfate sodium for knee osteoarthritis.
• In July 2026, US prescribing information for galcanezumab (EMGALITY) was updated to include revised Warnings and Precautions, while it’s approved indication for the preventive treatment of migraine remained unchanged.

Chronic Pain Drug Analysis & Competitive Landscape

The chronic pain drug chapter provides a detailed, market-focused review of approved therapies and the emerging Chronic Pain pipeline across Phase I-III clinical trials. It covers Chronic Pain mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the chronic pain treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the chronic pain therapeutics market.

Chronic Pain Approved Therapies

• Atogepant (AQUIPTA/QULIPTA): AbbVie

Atogepant is approved for migraine prophylaxis in more than 60 countries and is marketed as AQUIPTA in the EU and QULIPTA in the US, Canada, Israel, and Puerto Rico. CGRP receptor antagonists work to treat migraine by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide, which is thought to play a causal role in migraine.

• In April 2026, AbbVie presented results from a completed Phase III study which assessed atogepant with onabotulinumtoxinA at the American Academy of Neurology (AAN).
• In February 2026, AbbVie announced that it has received marketing approval in Japan for atogepant for the prevention of migraine attacks in adult patients.
• In August 2023, it was approved as a once-daily preventive treatment option for adults with chronic or episodic migraine who experience four or more migraine days per month on the basis of two trials PROGRESS and ADVANCE.

Chronic Pain Pipeline Analysis

• SL1002: Saol Therapeutics

SL-1002 is a novel injectable chemoneurolytic agent being developed specifically for chronic knee pain associated with osteoarthritis. It is designed as a single-treatment approach for persistent osteoarthritis-related knee pain, with Phase II evaluation completed and a Phase III study currently underway in patients with mild-to-moderate knee osteoarthritis.

• In April 2025, Saol Therapeutics reported that SL-1002 had advanced toward Phase III development for chronic knee pain associated with osteoarthritis following an FDA End-of-Phase II meeting that established a regulatory path for the program. In November 2025, Saol initiated the Phase III trial, evaluating SL-1002 as a single-dose treatment for knee pain associated with mild-to-moderate osteoarthritis.

Chronic Pain Market Outlook

The market outlook for chronic pain remains positive, driven by a growing patient population, increasing disease awareness, improved diagnosis, and a substantial unmet need for effective long-term therapies. Current approaches primarily focus on pain relief and improving physical function through pharmacological and non-pharmacological interventions; however, many patients continue to experience persistent pain and functional limitations. A growing pipeline of novel and targeted therapies is expected to further evolve the treatment landscape, while continued research and advances in personalized and multimodal approaches may improve patient outcomes, reduce disease burden, and support market growth.

Key findings from the Chronic Pain Market Forecast

• In 2025, the Chronic Pain Therapeutics Market Size in the US was around USD 8 billion. This figure is expected to grow significantly with the introduction of emerging therapies.
• The Chronic Pain Therapeutics Market Size of EU4 and the UK was estimated to be more than USD 3 billion in 2025.
• Among EU4 and the UK, Germany accounted for the highest Chronic Pain Market Share with approximately USD 951 million in 2025, followed by France with ~USD 800 million in the respective year, and UK capturing the least market with nearly USD 700 million in 2025.
• In 2025, the Chronic Pain Treatment Market Size was nearly USD 1 billion in Japan, which is anticipated to increase during the forecast period (2026–2036).

Chronic Pain Companies

• Collegium Pharmaceutical
• AbbVie
• Saol Therapeutics
• Novo Nordisk
• Eli Lilly and Company and more

Chronic Pain Drug Class/Insights into Leading Emerging Therapies (2026–2036 Forecast)

Novel Non-Opioid and Targeted Therapies: Emerging therapies represent an increasingly diversified approach in chronic pain, with candidates targeting chronic low back pain, osteoarthritis, migraine, fibromyalgia, and neuropathic pain through mechanism-specific, non-opioid, regenerative, and extended-release strategies. The pipeline includes biologics, monoclonal antibodies, small molecules, regenerative therapies, and extended-release formulations designed to provide sustained pain relief, improve functional outcomes, and address underlying drivers of chronic pain.

Chronic Pain Drug Uptake

This section focuses on the uptake rate of potential Chronic Pain drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the chronic pain drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The emerging treatment landscape for chronic pain is expected to be shaped by therapies with varying adoption rates based on their clinical efficacy, stage of development, safety profile, and ability to address key unmet needs. Zenagamtide, Retatrutide, and SL1002 are anticipated to achieve medium uptake, supported by their promising clinical potential and potential to address unmet treatment needs, although adoption may be influenced by factors such as clinical differentiation, regulatory timelines, pricing, reimbursement, and the need for additional clinical and long-term evidence.

In contrast, IncobotulinumtoxinA is expected to demonstrate medium-fast uptake, supported by its established therapeutic platform and potential role in chronic pain management, although uptake may be moderated by clinical positioning, treatment guidelines, and reimbursement considerations. Collectively, these therapies are expected to expand treatment options for chronic pain, improve disease management, and contribute to the gradual evolution of the treatment paradigm over the forecast period.

Detailed insights of emerging therapies' drug uptake is included in the report…

Chronic Pain Market Access and Reimbursement of Therapies

The Chronic Pain Therapeutics Market Report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

EU4 and the UK

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report.

Chronic Pain Therapies Price Scenario & Trends

Pricing and analogue assessment of chronic pain therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Chronic Pain Industry Experts and Physician Views

To keep up with Chronic Pain Therapeutics Market Trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on Chronic Pain Emerging Therapies, the evolving Chronic Pain Treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in chronic pain, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 30+ KOLs to gather insights at the country level. Leading centers such as Harvard University and Friedrich Schiller University Jena, Brigham and Women's Hospital, Aichi Medical University, among others, were consulted to validate clinical practices, treatment patterns, and emerging therapeutic perspectives.

Their opinion helps understand and validate current and emerging chronic pain therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in chronic pain.

Chronic Pain Report Qualitative Analysis: SWOT and Attribute Analysis

We perform qualitative and Chronic Pain Therapeutics Market Intelligence analysis using various approaches, such as SWOT analysis and attribute analysis. In the SWOT analysis of chronic pain, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Attribute analysis analyzes Chronic Pain emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team analyzed promising emerging therapies for chronic pain based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Chronic Pain Market Report

• The Chronic Pain Therapeutics Market Report covers a segment of key events, an executive summary, and a descriptive overview, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Chronic Pain treatment landscape.
• A detailed review of the Chronic Pain Therapeutics Market, historical and forecasted Chronic Pain Market Size, Chronic Pain Drugs Market Share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Chronic Pain Therapeutics Market Report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Chronic Pain Drugs Market.

Chronic Pain Market Report Insights

• Chronic Pain Patient Population Forecast
• Chronic Pain Therapeutics Market Size
• Chronic Pain Pipeline Drugs Analysis
• Chronic Pain Market Size and Trends
• Chronic Pain Market Opportunity (Current and Forecasted)

Chronic Pain Market Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI) - enabled Market Research Report
• 11-year forecast
• Chronic Pain Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Chronic Pain Treatment Addressable Market (TAM)
• Chronic Pain Competitive Landscape
• Chronic Pain Major Companies Insights
• Chronic Pain Price Trends and Analogue Assessment
• Chronic Pain Therapies Drug Adoption/Uptake
• Chronic Pain Therapies Peak Patient Share Analysis

Chronic Pain Market Report Assessment

• Current Chronic Pain Treatment Practices
• Chronic Pain Unmet Needs
• Chronic Pain Clinical Development Analysis
• Chronic Pain Emerging Drugs Product Profiles
• Chronic Pain Market Attractiveness
• Chronic Pain Qualitative Analysis (SWOT and Attribute analysis)

Key Questions Answered in the Chronic Pain Therapeutics Market Report

Chronic Pain Market Insights

• What was the chronic pain market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of chronic pain?
• What are the disease risks, burdens, and unmet needs of chronic pain?
• What will be the growth opportunities across the 7MM concerning the patient population with chronic pain?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of chronic pain? What are the current guidelines for treating chronic pain in the US, Europe, and Japan?

Reasons to Buy the Chronic Pain Market Report

• The Chronic Pain Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the chronic pain drugs market.
• Bottom-up forecasting builds from the affected population to product forecasts, delivering a robust, data-driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease, Chronic Pain Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the Chronic Pain drugs market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and Chronic Pain emerging therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Chronic Pain drugs market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)   enabled report summarizes and simplifies complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Stay updated with us for Recent Articles

• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
• How are Neurostimulation Devices Playing a Vital Role in the Treatment of Chronic Pain?
• Global Chronic Pain Associated With Painful Diabetic Neuropathy Market Landscape
• Emerging Therapies in the Chronic Pain Pipeline Transforming the Chronic Pain Market Landscape
• Chronic Pain Market Infographics
• New DelveInsight Blogs